Infections associated with cardiac electronic implantable devices: economic perspectives and impact of the TYRX™ antibacterial envelope.
The occurrence of cardiac implantable electronic devices (CIED) infections and related adverse outcomes have an important financial impact on the healthcare system, with hospitalization length of stay (2-3 weeks on average) being the largest cost driver, including the cost of device system extraction and device replacement accounting for more than half of total costs. In the recent literature, the economic profile of the TYRX™ absorbable antibacterial envelope was analysed taking into account both randomized and non-randomized trial data. Economic analysis found that the envelope is associated with cost-effectiveness ratios below USA and European benchmarks in selected patients at increased risk of infection. Therefore, the TYRX™ envelope, by effectively reducing CIED infections, provides value according to the criteria of affordability currently adopted by USA and European healthcare systems.
['Boriani|Giuseppe|G|0000-0002-9820-4815', 'Vitolo|Marco|M|0000-0002-5196-6249', 'Wright|David Justin|DJ|', 'Biffi|Mauro|M|', 'Brown|Benedict|B|', 'Tarakji|Khaldoun G|KG|', 'Wilkoff|Bruce L|BL|']
D000900:Anti-Bacterial Agents D003362:Cost-Benefit Analysis D017147:Defibrillators, Implantable D004581:Electronics D006801:Humans D016459:Prosthesis-Related Infections
Infections Economics Cardiac implantable electronic devices Hospitalization Cost Cost-effectiveness Antibiotics